SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing significant momentum driven by a newly announced collaboration with NVIDIA to integrate its QNX safety-critical OS into advanced edge AI systems, fueling a community-led surge in retail interest and trending status. Investors are increasingly optimistic about the companys turnaround, pointing to growing royalty backlogs, cybersecurity demand, and the stock's recent break past key resistance levels as signs of a long-awaited revaluation.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is currently trending amid a significant strategic shift as the company acquires Brazil's Serra Verde Group in a transaction aimed at securing a non-Asian source for key magnetic rare earth elements. While investors and market analysts are actively debating the potential for long-term supply chain dominance and government-backed infrastructure status, the stock is seeing heightened volatility due to concerns over share dilution and the aggressive positioning of short sellers.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing high volatility and retail interest driven by an executive order to fast-track psychedelic research, which market participants view as a significant catalyst for ibogaine-based treatments. The community is actively debating the stock's potential for a massive short squeeze given its exceptionally low float, while cautious traders warn of the risks associated with micro-cap volatility and the potential for aggressive dilution.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is seeing significant volatility as investors react to a sudden leadership shakeup involving the resignation of the CEO and CFO, alongside ongoing concerns about delayed power milestones and the search for an anchor tenant. While some community members are treating the pullback as a buying opportunity given the project's long-term scale and infrastructure potential, others are increasingly skeptical, pointing to the lack of revenue and the potential for further downside before stabilization.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is experiencing high volatility as investors weigh strong quarterly earnings and aggressive share buybacks against cautious forward guidance and the departure of a long-standing board member. The community remains deeply divided, with many retail traders actively buying the dip, while others express concerns over institutional selling pressure and potential downside risks.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is currently garnering significant attention as retail and institutional investors alike speculate on a potential buyout or major partnership, driven by excitement over the firm's oncology pipeline and positive clinical trial data. Community sentiment is highly polarized, with optimistic long-term holders highlighting upcoming trial milestones and regulatory progress, while vocal skeptics point to the stock's long-term performance and historical dilution as reasons for caution.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying following a strategic announcement to redomicile in the U.S. and resolve tax-related concerns, effectively neutralizing a recent short-seller report. The community is actively debating the stock's potential for a short squeeze and long-term valuation shifts as investors shift focus toward upcoming commercial manufacturing milestones and institutional accumulation.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI Life Sciences N.V.

ATAI is trending as the market reacts to an executive order aimed at fast-tracking psychedelic drug research for veterans and mental health, fueling speculation about clinical acceleration and potential pharmaceutical partnerships for the company's BPL-003 candidate. Community sentiment is divided between optimism regarding recent pipeline milestones and clinical validation versus frustration over historical share dilution and persistent intraday price weakness.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending as investors react to a large upsized stock offering intended to fuel data center expansion and debt repayment, fueling community debate over the impact of dilution versus the company's long-term growth potential in AI infrastructure. Despite the share issuance, bullish sentiment remains strong as traders highlight the firm's strategic focus on securing power for hyperscale data centers and anticipate upcoming announcements regarding lease agreements in Kentucky.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant downward pressure as investors react to a failed orbital deployment where a satellite was placed in an incorrect orbit due to a launch vehicle error. While the company maintains that the loss is covered by insurance and its broader constellation roadmap remains intact, the community is actively debating the reliability of external launch providers and the potential for cascading delays in future deployments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The order calls on the FDA to give priority to select psychedelic treatments that have demonstrated positive results in preliminary research.&nbsp;</li><li>The treatments could qualify for priority review, enabling regulators to assess them faster while upholding safety requirements.</li><li>COMP360, Compass’s psilocybin therapy in late-stage trials, has shown relief within a day, with effects lasting up to six months after one or two doses.&nbsp;</li></ul>Compass Pathways (CMPS) stock gained overnight on Sunday as the company voiced support for the White House’s executive action to speed up research, approval, and availability of psychedelic-based treatments.The company specializes in psilocybin therapies, which stand to benefit from faster regulatory timelines tied to its lead candidate.&nbsp;<h2 class="st-heading-2">Regulatory Changes To Speed Access</h2>President Donald Trump on Saturday signed the order to speed up the development, review, and accessibility of treatments targeting complex psychiatric conditions. The policy outlines a coordinated effort across federal agencies to reduce regulatory delays and expand research opportunities. The order instructs the Food and Drug Administration (FDA) to prioritize certain psychedelic drugs that have already shown promise in early studies.&nbsp;These therapies may receive special review vouchers, allowing regulators to evaluate them more quickly without compromising safety standards. In parallel, the FDA and the Drug Enforcement Administration are tasked with designing pathways that permit eligible patients to access investigational treatments still under review, provided they meet baseline safety criteria.<h2 class="st-heading-2">Compass Lead Candidate Gains Momentum</h2>Compass said it is already engaged in ongoing review discussions with the FDA, positioning it to capitalize on the policy shift as it advances treatment for depression.<blockquote>“Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin,” said CEO Kabir Nath.</blockquote>At the center of this development is COMP360, the company’s synthetic psilocybin therapy currently in late-stage trials. Phase 3 trial findings suggest the treatment may produce rapid improvements, with patients experiencing relief within a day and sustained benefits lasting about six months after just 1 or 2 doses.<a href="https://stocktwits.com/symbol/CMPS">Compass Pathways’ stock</a> was up over 2%&nbsp;as of its last after-hours close. Peers&nbsp;Enveric Biosciences and ATAI Life Sciences were up over 3.5% and 1.1%, respectively.&nbsp;The company’s study includes data from more than 1,000 participants, indicating a generally manageable safety profile with short-lived side effects. Beyond depression, Compass is expanding its focus to PTSD, including collaboration with Veterans Affairs programs to explore treatment options.<h2 class="st-heading-2">What Are Retail Traders Saying?&nbsp;</h2>On Stocktwits, retail sentiment for Compass Pathways remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels,&nbsp;which have surged by 2,000% over the past seven days.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_04_19_214919_png_16ee490f83.webp" alt="CMPS’s Sentiment Meter and Message Volume as of 21:45 p.m. ET on Apr.19, 2026 | Source: Stocktwits" width="930" height="97"><figcaption>CMPS’s Sentiment Meter and Message Volume as of 21:45 p.m. ET on Apr.19, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user&nbsp;<a href="https://stocktwits.com/Canvasback33/message/650726549">expressed</a> optimism about COMP360 receiving approval and availability.&nbsp;“EO [executive order] was the last hurdle in my mind for this stock. Federal govt has cleared the run way for psychedelic medicine and the FDA is on board. I truly believe this will be approved and is going to market. This is the future of mental health.”<stembedurl>https://stocktwits.com/Canvasback33/message/650726549</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Millionaire11/message/650726940">said</a>:&nbsp;“This is not a sell the news event. This news was not expected. This will skyrocket upon FDA approval anticipation. Once FDA approved, I could see a sell the news event but for now enjoy the gains this week.”<stembedurl>https://stocktwits.com/Millionaire11/message/650726940</stembedurl>CMPS stock has declined over 3% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-china-surge-shows-pricing-power-matters-in-a-supply-crunch-retail-bulls-take-notice/cZJUsxBRIUG">Apple’s China Surge Shows Pricing Power Matters In A Supply Crunch – Retail Bulls Take Notice</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ProKidney (PROK) is developing rilparencel, an autologous cellular therapy aimed at slowing kidney function decline in patients with chronic kidney disease/ Photo credit: Getty Images

CMPS Stock Surges As White House Psychedelic Push Prompts FDA Review, Boosts COMP360 Prospects

CMPS Stock - On Saturday, President Trump approved a measure to accelerate the development, evaluation, and availability of therapies for mental health disorders. 

CMPS Stock Jumps Overnight After Trump Order Fast-Tracks Psychedelic Therapies

Equity

On Saturday, President Trump approved a measure to accelerate the development, evaluation, and availability of therapies for mental health disorders. 


<ul class="summary-bullets"><li>The report, citing sources, said that the federal government is going to look closely at ibogaine’s safety and effectiveness.&nbsp;</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>The Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, the report added.</li></ul>Shares of Psyence Biomedical (PBM) more than doubled on Thursday following media reports that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.Shares of the company, which is advancing nature-derived psilocybin and ibogaine therapies, traded 141% higher at the time of writing, on track for its best session to date if gains hold.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs, based in Africa, as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Trump’s Upcoming Executive Order</h2>CBS News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a &nbsp;Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.An official told CBS News that medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's "snake oil" or a legitimate treatment.Other companies in the field of psychedelics, including Clearmind Medicine (CMND), AtaiBeckley (ATAI), GH Research (GHRS), and Compass Pathways (CMPS) are also trading higher on the news.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.A Stocktwits user noted that PBM stock is subject to “wild swings.”<stembedurl>https://www.stocktwits.com/dippin_stocks/message/650500248</stembedurl>Another user opined that the stock is going to be “highly volatile” but reach double digit.<stembedurl>https://www.stocktwits.com/momoneyinfla/message/650499935</stembedurl><a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has fallen by about 95% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM">ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments PR Newswire VANCOUVER, BC, Feb. 27...

New Strong Sell Stocks for Jan. 13

ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

<ul class="summary-bullets"><li>GH Research is scheduled to update on the FDA status of GH001 and outline its global Phase 3 plans for treatment-resistant depression on Monday.</li><li>The update follows the company’s submission of a complete response to the FDA after a prior clinical hold.</li><li>Progress across competing psychedelic-based depression programs has increased focus on the stock.</li></ul>Shares of GH Research PLC drew increased retail attention on Monday ahead of a scheduled update on its FDA Investigational New Drug application for GH001, the company’s inhaled therapy for treatment-resistant depression, and its plans for a global Phase 3 program, due at 7:00 a.m. EST.<h2 class="st-heading-2">Phase 3 Program And FDA Update In Focus</h2>The update follows the company’s June disclosure that it submitted a complete response to the FDA addressing a previously announced clinical hold on the IND. At the time, GH Research said the submission included completed toxicology studies and comprehensive responses to the agency’s requests, adding that it had worked closely with regulators and submitted the response ahead of schedule.<h2 class="st-heading-2">GH001 Data Anchors Development Path</h2>GH001 is GH Research’s lead experimental therapy, delivered through a proprietary inhalation system and designed to treat patients with treatment-resistant depression, a condition where standard antidepressants have failed.In February 2025, the company reported results from a Phase 2b study involving 81 patients. Those treated with GH001 showed a significant improvement in depression symptoms within eight days, with scores on a standard clinical scale falling by an average of 15.5 points more than placebo. The difference was statistically significant.Over half of the patients receiving GH001 achieved remission by Day 8, compared with none in the placebo group. The company said all secondary study goals were met, and the treatment was well tolerated, with no serious adverse events reported during the blinded phase of the trial.Longer-term follow-up data showed sustained benefits. Among patients who completed six months of follow-up, nearly 78% remained in remission, with most requiring only a small number of additional treatments. As of late January 2025, the company reported no serious safety issues during this extended period.<h2 class="st-heading-2">Psychedelic Race Intensifies</h2>In November, H.C. Wainwright lowered its price target on GH Research to $35 from $40 while maintaining a ‘Buy’ rating, citing competitive momentum from programs such as Atai Beckley’s BPL-003 and AbbVie’s GM-2505, as well as the prior FDA hold.In October, Needham initiated coverage with a ‘Buy’ rating and a $19 price target, citing GH001’s Phase 2 efficacy and remission data and estimating potential U.S. sales of $1.9 billion by 2035.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for GH Research was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:968/143;" src="https://news.stocktwits-cdn.com/ghrs_ss_png_215c6b80c9.webp" alt="ghrs ss.png" width="968" height="143"><figcaption>GHRS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user grouped GH Research alongside names like Disney, Marathon Digital, Critical Metals and Navitas Semiconductor, saying the stock continues to sit within a cluster of “hot themes” across the market.<stembedurl>https://stocktwits.com/JoyceFernandez/message/640797658</stembedurl>Another user said they plan to sell part of their position around the FDA update to lock in gains and hold the rest into the next company update later in the quarter.<stembedurl>https://stocktwits.com/NoobFriendly/message/640797043</stembedurl><a href="https://stocktwits.com/symbol/GHRS">GH Research’s stock</a> has risen 89% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the GH Research logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment

GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression.

<ul class="summary-bullets"><li>The analyst noted that sponsors must continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health.</li><li>Jefferies added that it believes Atai Beckley's (ATAI) proprietary psychedelics have promise.</li><li>The AdvisorShares Psychedelics ETF (PSIL), which invests in the emerging psychedelic drugs sector, traded 1.3% higher at the time of writing.</li></ul>Jefferies analyst Andrew Tsai now sees positive tailwinds forming for non-recreational psychedelics after President Trump signed an executive order on Thursday directing his administration to reclassify marijuana.The firm now sees non-recreational psychedelics eventually follow suit, as long as sponsors continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health. This, the analyst believes, is arguably a function of time.&nbsp;Jefferies added that it believes pharmaceutical company Atai Beckley's (<a href="https://stocktwits.com/symbol/ATAI">ATAI</a>) proprietary psychedelics have promise. AtaiBeckley’s pipeline includes investigational therapies for treatment-resistant depression and social anxiety disorder.Shares of psychedelics-related stocks rallied on Friday. While ATAI stock traded 0.4% higher at the time of writing, Supernus (<a href="https://stocktwits.com/symbol/SUPN">SUPN</a>) and Cybin (<a href="https://stocktwits.com/symbol/CYBN">CYBN</a>) shares rose about 5%.The AdvisorShares Psychedelics ETF (<a href="https://stocktwits.com/symbol/PSIL">PSIL</a>), which invests in the emerging psychedelic drugs sector, also traded 1.3% higher.<h2 class="st-heading-2">Trump Cannabis Order</h2>President Donald Trump on Thursday <a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-stock-rise-as-trump-signs-executive-order-to-lower-marijuana-restrictions/cLegUFuREr0">signed</a> an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.” Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. The Centers for Medicare &amp; Medicaid Services (CMS) is also working on a plan to test making some Medicare patients eligible for therapies derived from cannabinoids or compounds derived from the Cannabis plant.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PSIL fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while sentiment around ATAI also took a dip to ‘extremely bearish’ levels.Sentiment around SUPN stayed ‘neutral,’ while sentiment around CYBN stayed ‘extremely bullish’.A Stocktwits user highlighted a positive study from 2022 on Psilocybin, a naturally occurring psychedelic compound, in treating depression symptoms.<stembedurl>https://www.stocktwits.com/DJS777/message/639663641</stembedurl>As per the study published in the New England Journal of Medicine, participants reported a greater reduction in levels of depression three weeks after taking a 25 mg dose of psilocybin, compared to those who took the lowest 1 mg dose.PSIL has gained 68% this year and by 76% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-on-track-for-worst-day-in-about-9-months/cLe0RFtREsu">Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Digitally generated image of brain filled with multicolored particles. | Source: Getty Images

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.  

Enhanced Fortifies Executive Leadership Team & Board of Directors

Enhanced Fortifies Executive Leadership Team & Board of Directors Enhanced Fortifies Executive Leadership Team & Board of Directors PR Newswire NEW YORK, Nov. 19, 2025 Co-Founder Maximilian Martin...

atai Life Sciences (ATAI) Upgraded to Buy: Here's Why

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know

atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

The stock is rallying as traders react to a new executive order aiming to fast-track FDA reviews and funding for psychedelic research.

Specific focus is building around pharmaceutical-grade ibogaine assets and the competitive advantage they may gain under new government initiatives.

High-conviction investors are monitoring upcoming Phase 3 trial data and potential partnership deals expected to fuel long-term valuation growth.

Market attention is shifting toward the potential for institutional and government-led capital flows into well-positioned CNS therapeutic companies.

Traders are debating a broader repricing of the psychedelic sector following shifted regulatory sentiment regarding mental health and veteran care.

ATAI
AtaiBeckley Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ATAI News

ATAIAtaiBeckley Inc.